Genetic Engineering & Biotechnology News

09/16/2026

Consolidating Antibody Discovery Data with an AI Platform

FairJourney Bio ( ) selected the Sapio Scientific AI platform to replace spreadsheet-based records and manual reporting processes across its international operation.

Sapio Sciences

FairJourney Bio runs scientific discovery programs of genuine depth and complexity across multiple international sites.

09/16/2026

New eBook! Unlocking Microbiome Function with Anaerobic Workflows and Metabolic Phenotyping

This eBook explores how researchers can move beyond correlation and towards mechanism in microbiome research—from preserving physiologically relevant microbial communities to directly measuring microbial function through phenotyping.

Download this FREE eBook sponsored by Biolog: https://hubs.li/Q04vzTVf0

09/16/2026

Regenerative Medicine in the Bronze Age: MSCs and MSC-EVs Leading the Way

The field of regenerative medicine is gaining momentum. Mesenchymal stem cells (MSCs) remain central to this field, with expanding applications as direct therapies and as producers of MSC-derived extracellular vesicles (MSC-EVs). This article examines the biological and regulatory factors shaping their promise.

The field of regenerative medicine is gaining momentum. Mesenchymal stem cells (MSCs) remain central to this field, with expanding applications as direct therapies and as producers of MSC-derived extracellular vesicles (MSC-EVs). This article examines the biological and regulatory factors shaping th...

09/16/2026

Microprotein Atlas Links Brain Immune Cell Dysfunction to Alzheimer’s

Built from transcriptomic and mass spectrometry data, the Salk Institute atlas uncovered more than 1,000 previously uncharacterized microproteins and pointed to a potential connection between one microprotein and microglial dysfunction in Alzheimer’s disease.

A new microprotein atlas of the human frontal cortex reveals more than 1,000 previously uncharacterized microproteins.

09/16/2026

Novartis Loses More than Market Value After Phase III Failure

‘The party’s over,’ top shareholder declares, demanding pharma giant’s board keep closer eye on acquisitions; Analysts pinpoint competitors likely to benefit, while some market watchers cut back peak sales forecasts for DM1 candidate.

M. David Samra, managing director at Artisan Partners and founding partner of International Value Group, called on the board—specifically, its chairman Giovanni Caforio—to strengthen its oversight of the company’s acquisitions.

Don't miss Alex Phillipidis' latest StockWatch!

Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, Novartis and Ionis Pharmaceuticals acknowledged that pelacarsen failed the Phase III Lp(a)HORIZON trial by missing its primary endpoint of reducing the risk of cardiovascular events. Two days earlier, Novartis...

09/15/2026

Mark Your Calendar! Advancing Microbial-Derived Biologics from Scale-Up to Commercial Production

Register for this FREE webinar sponsored by WuXi Biologics: https://hubs.li/Q04xyVYk0

09/15/2026

Harnessing Real-Time Data

Using process analytical technologies (PAT) to collect and harness real-time data in automated, closed-loop systems is the future of bioprocessing. See what industry experts from Eppendorf, Hamilton Medical AG, , and Cytiva told GEN.

Using process analytical technologies (PAT) to collect and harness real-time data in automated, closed-loop systems is the future of bioprocessing.

09/15/2026

Don't Miss Out! Embedding Regulatory Strategy in Cell and Gene Therapy Development

Broadcast Date: Thursday, September 17, 2026
Time: 08:00 PDT, 11:00 EDT, 17:00 CET

In this GEN webinar, experts from Rose BioSolutions, a CDMO and Cell Solutions organization formed from Charles River Laboratories’ businesses, will discuss how integrating regulatory strategy at the earliest stages of development can reduce overall risk and improve program outcomes.

Register for this FREE webinar sponsored by Rose BioSolutions: https://hubs.li/Q04vd2KT0

09/15/2026

Why Does a Particular Genetic Variant Lead to Accelerated Huntington Disease Development?

University of British Columbia findings provide some of the strongest human evidence to date that expansion of the Huntington mutation is a key factor in disease progression.

Findings provide some of the strongest human evidence to date that expansion of the Huntington mutation is a key factor in disease progression.

09/14/2026

Cancer Treatment Genetic Effects in Healthy Cells May Reveal Clues to Side Effects and Resistance

The study findings might also help inform development of targeted treatments that destroy cancer cells while leaving normal tissue unharmed. The results are from a study by scientists at Wellcome Sanger Institute, University of Cambridge, University College London, and collaborators.

Study findings might also help inform development of targeted treatments that destroy cancer cells while leaving normal tissue unharmed.